π£ VC round data is live. Check it out!
- Public Comps
- Aberdeen Group
Aberdeen Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aberdeen Group and similar public comparables like Onex, Australian Foundation Investment Company, Soochow Securities, Azimut Group and more.
Aberdeen Group Overview
About Aberdeen Group
Aberdeen Group PLC provides a variety of investment services. It operates in the following segments: Adviser, Investments, and Other. The investments segment involves a asset management business that provides investment solutions for Institutional, Wholesale, and Insurance Partners clients. The Adviser business provides platform services to wealth managers and advisers along with the Groupβs Managed Portfolio Service (MPS) business. The majority of the company's income comes from the United Kingdom.
Founded
2005
HQ

Employees
4.6K
Website
Sectors
Financials (LTM)
EV
$7B
Valuation Multiples
Start free trialAberdeen Group Financials
Aberdeen Group reported last 12-month revenue of $2B and EBITDA of $432M.
In the same LTM period, Aberdeen Group generated $1B in gross profit, $432M in EBITDA, and $379M in net income.
Revenue (LTM)
Aberdeen Group P&L
In the most recent fiscal year, Aberdeen Group reported revenue of $2B and EBITDA of $415M.
Aberdeen Group is profitable as of last fiscal year, with EBITDA margin of 18% and net margin of 23%.
Financial data powered by Morningstar, Inc.
Aberdeen Group Stock Performance
Aberdeen Group has current market cap of $6B, and enterprise value of $7B.
Market Cap Evolution
Aberdeen Group's stock price is $3.25.
Aberdeen Group share price increased by 15.6% in the last 30 days, and by 39.9% in the last year.
Aberdeen Group has an EPS (earnings per share) of $0.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $6B | 1.2% | 15.6% | 8.8% | 39.9% | $0.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAberdeen Group Valuation Multiples
Aberdeen Group trades at 3.8x EV/Revenue multiple, and 15.2x EV/EBITDA.
EV / Revenue (LTM)
Aberdeen Group Financial Valuation Multiples
As of May 23, 2026, Aberdeen Group has market cap of $6B and EV of $7B.
Aberdeen Group has a P/E ratio of 15.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aberdeen Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Aberdeen Group Margins & Growth Rates
Aberdeen Group decreased revenue by 25% but EBITDA grew by 10% in the last fiscal year.
In the most recent fiscal year, Aberdeen Group reported EBITDA margin of 18% and net margin of 23%.
Aberdeen Group Margins
Aberdeen Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Aberdeen Group Operational KPIs
Aberdeen Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Aberdeen Group's Rule of 40 is 1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aberdeen Group's Rule of X is (37%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Aberdeen Group Competitors
Aberdeen Group competitors include Onex, Australian Foundation Investment Company, Soochow Securities, Azimut Group, Cenergy Holdings, SDIC Capital, Capital Securities Corp., Hedef Holding, Warehouses De Pauw and Investec UK.
Most Aberdeen Group public comparables operate across Asset Management.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.8x | β | 9.6x | β | |||
| 24.8x | β | β | β | |||
| 11.4x | 11.3x | β | β | |||
| 3.1x | 3.1x | 6.3x | 6.3x | |||
| 2.6x | 2.4x | 15.3x | 14.4x | |||
| (5.5x) | (5.2x) | (12.5x) | β | |||
| 24.4x | β | β | β | |||
| 1387.6x | β | (205.1x) | β | |||
This data is available for Pro users. Sign up to see all Aberdeen Group competitors and their valuation data. Start Free Trial | ||||||
Aberdeen Group M&A Activity
Aberdeen Group has acquired 5 companies to date.
Last acquisition by Aberdeen Group was on December 12th 2025. Aberdeen Group acquired MFS Intermediate IT for undisclosed valuation.
Latest Acquisitions by Aberdeen Group
| Description | MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors. | Tritax Group is a London-headquartered fund manager specializing in high-quality logistics real estate across Europe. The firm oversees investment vehicles including Tritax Big Box and Tritax EuroBox, targeting well-located warehouses for institutional investors. Tritax Group executes acquisitions, developments, and asset management in key logistics hubs. | Interactive Investor is a Manchester-based subscription-based investment platform serving over 400,000 customers in the UK. Founded in 1995 and acquired by abrdn in 2022, it offers execution-only trading in stocks, funds, and ETFs with a flat Β£4.99 to Β£19.99 monthly fee structure. The site attracts 8 million unique annual visitors through independent research tools and direct investment access. It ranks as the UK's largest flat-fee platform by client numbers and assets under administration exceeding Β£50 billion. | New York-based Finimize runs a global finance community platform distributing daily newsletters, mobile app content, and insights on markets, investments, and economic trends to engaged subscribers worldwide. | |
| HQ Country | |||||
| HQ City | Boston, MA | β | Glasgow | London | |
| Deal Date | 12 Dec 2025 | 29 Oct 2025 | 2 Dec 2021 | 29 Oct 2021 | |
| Valuation | undisclosed | undisclosed | $2B | $110M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Aberdeen Group acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Aberdeen Group Investment Activity
Aberdeen Group has invested in 11 companies to date.
Latest investment by Aberdeen Group was on November 12th 2025. Aberdeen Group invested in FNZ in their $650M Undisclosed stage round (EV/Revenue multiple of ).
Latest Investments by Aberdeen Group
| Description | FNZ is a London-headquartered wealth management platform powering end-to-end operations for banks, insurers, and asset managers globally. The cloud-native system handles financial planning, trade execution, custody, portfolio management, and retirement services via API integrations. FNZ serves over 12 million clients through partnerships with Aviva, Standard Life, and UBS, incorporating acquisitions like New Access for onboarding and Appway for digital advice. | Glycomine is a San Francisco-based early-stage biotechnology firm focused on enzyme replacement therapies for rare genetic disorders lacking approved treatments. Targeting the 95 percent of 7,000 known rare diseases without FDA options, it advances protein therapeutics to address unmet needs in metabolic and lysosomal storage conditions. | Atalanta Therapeutics is a biotechnology company developing RNA interference therapies for neurodegenerative diseases. Leveraging its proprietary RNA delivery platform, the firm targets ALS and Parkinson's, with preclinical programs silencing disease-causing genes in the central nervous system. Backed by ARCH Venture Partners, Atalanta operates from Boston. | Aviceda Therapeutics is a Boston-based clinical-stage biotechnology company developing glycan therapeutics for glyco-immune diseases. The firm targets chronic inflammation in areas like ophthalmology, fibrosis, neurology, and oncology with lead candidates AVD-104 for dry eye disease, AVD-302 for diabetic retinopathy, and AVD-401 for retinoblastoma. Aviceda employs proprietary podocyte technology and high-throughput screening to engineer multivalent glycan compounds that modulate innate immune cells. | |
| HQ Country | |||||
| HQ City | London | San Francisco, CA | Boston, MA | β | |
| Deal Date | 12 Nov 2025 | 16 Apr 2025 | 28 Jan 2025 | 7 Jan 2025 | |
| Round | Undisclosed stage | Series C | Series B | Series C | |
| Raised | $650M | $115M | $97M | $208M | |
| Investors | Aberdeen Group; Aviva; CPP Investments; FirstCape; Generation Investment Management; La Caisse; Motive Partners; Ninety One; Nucleus Financial; Temasek Holdings | Aberdeen Group; Abingworth; Advent Life Sciences; Asahi Kasei Corporate Venture Capital; Chiesi Ventures; CTI Life Sciences Fund; Novo Holdings; Remiges Ventures; RiverVest; Sanderling Ventures; Sanofi Ventures | Aberdeen Group; EQT; F-Prime; GHR Foundation; MiraeAsset Financial Group; Novartis Venture Fund; Pictet Alternative Advisors; RiverVest; Sanofi Ventures | Aberdeen Group; Blue Owl; Catalio Capital Management; Digitalis Ventures; Enavate Sciences; Jeito Capital; Logos Capital; Longitude Capital; Marshall Wace; Omega Funds; OrbiMed; TCG Crossover | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Aberdeen Group investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aberdeen Group
| When was Aberdeen Group founded? | Aberdeen Group was founded in 2005. |
| Where is Aberdeen Group headquartered? | Aberdeen Group is headquartered in United Kingdom. |
| How many employees does Aberdeen Group have? | As of today, Aberdeen Group has over 4K employees. |
| Who is the CEO of Aberdeen Group? | Aberdeen Group's CEO is Jason Michael Windsor. |
| Is Aberdeen Group publicly listed? | Yes, Aberdeen Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Aberdeen Group? | Aberdeen Group trades under ABDN ticker. |
| When did Aberdeen Group go public? | Aberdeen Group went public in 2006. |
| Who are competitors of Aberdeen Group? | Aberdeen Group main competitors include Onex, Australian Foundation Investment Company, Soochow Securities, Azimut Group, Cenergy Holdings, SDIC Capital, Capital Securities Corp., Hedef Holding, Warehouses De Pauw, Investec UK. |
| What is the current market cap of Aberdeen Group? | Aberdeen Group's current market cap is $6B. |
| What is the current revenue of Aberdeen Group? | Aberdeen Group's last 12 months revenue is $2B. |
| What is the current revenue growth of Aberdeen Group? | Aberdeen Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Aberdeen Group? | Current revenue multiple of Aberdeen Group is 3.8x. |
| Is Aberdeen Group profitable? | Yes, Aberdeen Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aberdeen Group? | Aberdeen Group's last 12 months EBITDA is $432M. |
| What is Aberdeen Group's EBITDA margin? | Aberdeen Group's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Aberdeen Group? | Current EBITDA multiple of Aberdeen Group is 15.2x. |
| What is the current FCF of Aberdeen Group? | Aberdeen Group's last 12 months FCF is $455M. |
| What is Aberdeen Group's FCF margin? | Aberdeen Group's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Aberdeen Group? | Current FCF multiple of Aberdeen Group is 14.4x. |
| How many companies Aberdeen Group has acquired to date? | As of May 2026, Aberdeen Group has acquired 5 companies. |
| What was the largest acquisition by Aberdeen Group? | $5B acquisition of Aberdeen Asset Management on 6th March 2017 was the largest M&A Aberdeen Group has done to date. |
| What companies Aberdeen Group acquired? | Aberdeen Group acquired Aberdeen Asset Management, Interactive Investor, Finimize, MFS Intermediate IT, and Tritax Group. |
| In how many companies Aberdeen Group has invested to date? | As of May 2026, Aberdeen Group has invested in 11 companies. |
| What was the last Aberdeen Group investment? | On 12th November 2025 Aberdeen Group invested in FNZ, participating in a $650M Undisclosed stage round, alongside Aviva, CPP Investments, FirstCape, Generation Investment Management, La Caisse, Motive Partners, Ninety One, Nucleus Financial, and Temasek Holdings. |
| In what companies Aberdeen Group invested in? | Aberdeen Group invested in FNZ, Aviceda Therapeutics, Trinity Gas Storage, Engrail Therapeutics, Glycomine, Atalanta Therapeutics, CTOS Digital, Radiant Biotherapeutics, Archax, Qlaris Bio, and Eagle Genomics. |
See public comps similar to Aberdeen Group
Lists including Aberdeen Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

